Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357642 · ClinicalTrials.gov registry record · Phase 3
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
A Phase 3 study, sponsored by Amphastar Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 373
- Enrollment target
NCT01357642 is a Phase 3 study that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 373 participants.
The verdict
NCT01357642, a Phase 3 study, has completed, sponsored by Amphastar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 373 participants
- Enrollment target
Study Summary
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the currently marketed Primatene® Mist (epinephrine CFC inhaler), in adolescent and adult subjects with asthma.
Interventions
- DRUG Placebo
- DRUG epinephrine inhalation aerosol
- DRUG Epinephrine inhalation aerosol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357642
The ClinicalTrials.gov registry entry for NCT01357642 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01357642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01357642 about?
NCT01357642 is a clinical study titled "Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients". This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the currently marketed Primatene® Mist (epinephrine CFC inhaler), in adole...
What is the current status of trial NCT01357642?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 373 participants. The study started on 2011-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01357642?
The interventions under investigation include: Placebo (DRUG), epinephrine inhalation aerosol (DRUG), Epinephrine inhalation aerosol (DRUG).
Who is sponsoring clinical trial NCT01357642?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.